A Pilot Trial of Remotely-Supervised Transcranial Direct Current Stimulation (RS-tDCS) to Enhance Motor Learning in Progressive Multiple Sclerosis (MS)
Status: | Recruiting |
---|---|
Conditions: | Neurology, Neurology, Multiple Sclerosis |
Therapuetic Areas: | Neurology, Other |
Healthy: | No |
Age Range: | 18 - 70 |
Updated: | 10/6/2018 |
Start Date: | April 15, 2018 |
End Date: | April 2020 |
Contact: | Guadalupe Zuniga-estrada |
Email: | Guadalupe.Zuniga-Estrada@nyumc.org |
Phone: | 1 646 501 7506 |
This is a randomized, double-blind pilot clinical trial to test a novel treatment approach to
rehabilitate fine motor function in individuals living with progressive multiple sclerosis
(MS) using anodal transcranial direct current stimulation (tDCS) to augment manual dexterity
training. Treatment will be delivered to individuals at home using a state-of-the-art
remotely supervised tele-rehabilitation protocol, a major advantage for patients with respect
to ease of access, feasibility, reinforcement learning and minimal burden of in clinic study
visit participation. Improvements in fine motor skill will be assessed at each remote session
using a novel portable grip device that measures execution and adaptation or learning of
fingertip forces during grasp, which is more sensitive than standard measures of hand
function.
rehabilitate fine motor function in individuals living with progressive multiple sclerosis
(MS) using anodal transcranial direct current stimulation (tDCS) to augment manual dexterity
training. Treatment will be delivered to individuals at home using a state-of-the-art
remotely supervised tele-rehabilitation protocol, a major advantage for patients with respect
to ease of access, feasibility, reinforcement learning and minimal burden of in clinic study
visit participation. Improvements in fine motor skill will be assessed at each remote session
using a novel portable grip device that measures execution and adaptation or learning of
fingertip forces during grasp, which is more sensitive than standard measures of hand
function.
Inclusion Criteria:
- Definite MS diagnosis, progressive subtype
- 9HPT score between -1.0 and -4.0 standard deviations from age-based normative data
- Score of < 7.5 or less on the EDSS (with caregiver proxy required for those with
scores of 6.5 or greater)*
- Ability to understand the informed consent process and provide consent to participate
in the study
Exclusion Criteria:
- Primary neurologic, psychiatric or other medical disorder other than MS
- Use of upper extremity Botox injection within 3 months
- Current use of intrathecal Baclofen
- History of seizure disorder
- History of head trauma or medical device in head or neck
- Clinically significant abnormality on EKG
- Symbol Digit Modalities Test or SDMT score ≥3.0 SD from published norms
- WRAT-4 reading level below average (<85) (estimated general intellectual function)
- Skin disorder/sensitive near stimulation locations
We found this trial at
1
site
550 1st Ave
New York, New York 10016
New York, New York 10016
(212) 263-7300
Principal Investigator: Leigh Charvet, MD
Phone: 646-501-7506
New York University School of Medicine NYU School of Medicine has a proud history that...
Click here to add this to my saved trials